Last mentioned: Mar 23, 2026
Data Review
Expected first quarterly report on screening uptake and identification rates in Scotland.
Official Rollout
Scotland officially begins screening all newborns for the rare muscle disease.
Scotland Launch
Scotland officially begins nationwide screening for all newborns.
Data Evaluation
Expected first review of screening efficacy and treatment referral rates in Scotland.
Scottish Policy Review
Scottish health officials evaluate the feasibility of independent implementation.
Clinical Advocacy
Intense campaigning by rare disease groups for the inclusion of SMA in UK-wide screening.
UK NSC Recommendation
The UK National Screening Committee begins formal review of SMA for the newborn panel.
Zolgensma UK Approval
NHS England and Scotland reach deals to fund the world's most expensive gene therapy.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.